What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1367868

Cover Image

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1367868

Chronic Disease Markets for Sustained Release Injectables - Extended Coverage Version

PAGES: 225 Pages
DELIVERY TIME: 1-2 business days
PDF (Single User License)
USD 4850
PDF (Site License)
USD 6500
PDF (Enterprise License)
USD 9500

Add to Cart

“Chronic Disease Markets for Sustained Release Injectables: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

Product Code: SRK389F

Table of Contents

Executive Summary

  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers

Market Factors

  • Patient Compliance and Ease of Use
  • Healthcare Regulations
  • Managed Care Initiatives
  • Competitive Landscape
  • Risk Factors

Sustained release Formulation Technologies

  • Biodegradable Polymers
  • PEG
  • Polyether ester
  • BEPO (MedinCell)
  • ChroniJect (Oakwood Laboratories/PharmaSophia)
  • CriticalMix (Critical Pharmaceuticals)
  • Depofoam (Pacira)
  • FluidCrystal (Camarus)
  • LinkeRx (Alkermes)
  • Medisorb (Alkermes)
  • Medusa (Recipharm/Avadel)
  • Nanocrystals (Alkermes)
  • Optisomes (Talon/Spectrum)
  • PolyActive (Octoplus)
  • Q-Sphera (Midatech Pharma)
  • SynBiosys (Innocore)
  • TransCon (Ascendis)

Physical Process Control Methods

  • Supercritical Fluid
  • SCF for Nanoparticle Formulations
  • Formulplex (Supercritical Solutions)
  • Ferro
  • SCF extraction of emulsions (SFEE)

Sustained release Injectables - Development Factors

  • Formulation Factors
  • Stability
  • Administration Factors

SR Injectables - Product Analysis

  • Aripiprazole
  • Aripiprazole lauroxil
  • Bupivacaine
  • Buprenorphine
  • Cytarabine
  • Cytarabine & Daunorubicin
  • Doxorubicin
  • Estradiol
  • Exenatide
  • Fluphenazine decanoate
  • Goserelin acetate
  • Granisetron
  • Interferon(a)
  • Interferon(b)
  • Irinotecan
  • Lanreotide acetate
  • Leuprolide
  • Leuprolide Depot
  • Medroxyprogesterone
  • Naltrexone
  • Octreotide acetate
  • Olanzapine Pamoate
  • Paliperidone palmitate
  • Pasireotide
  • Pegvaliase-pqpz
  • Risperidone
  • Testosterone
  • Triptorelin
  • Triamcinolone acetonide
  • Vincristine sulfate

Chronic Disease Markets

  • Glycemic Control
  • AB101 (Rezolute)
  • Hormone Deficiency
  • human Growth Hormone/Ascendis Pharma
  • Addiction
  • CAM2038 (Camurus)
  • Pain Management
  • Posidur/Durect
  • Cardiology
  • Treprostinil/Ascendis Pharma
  • Neurology
  • Relday/Risperidone (DURECT/Zogenix)
  • Parkinson's Disease
  • Oncology
  • CAM2032 (Camurus)

Sustained Release Injectables - Selected Sector Analysis

  • Addiction
  • Glycemic Control
  • Infectious Disease
  • Hepatitis
  • Neurology
  • Schizophrenia
  • Bipolar Disorder
  • Oncology
  • Pain Management
  • Reproductive Health
  • Fertility
  • Endometriosis
  • Vasomotor Symptoms associated with Menopause

Company Profiles

  • Alkermes
  • Amylin
  • AntriaBio
  • Ascendis Pharma
  • AstraZeneca
  • Aurobundo
  • Avadel
  • Biomarin
  • Camurus
  • Critical Pharmaceuticals
  • Eli Lilly
  • Enzon
  • Ipsen
  • Janssen
  • NanOlogy
  • Novartis
  • OctoPlus
  • Oakwood Laboratories/PharmaSophia
  • Pacira
  • PhaseBio Pharmaceuticals
  • Recipharm AB
  • Roche
  • Sanofi
  • Taiwan Liposome Company
  • Xbrane Bipharma
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!